Martuscello, Regina T.
Chen, Meng-Ling
Reiken, Steven
Sittenfeld, Leah R.
Ruff, David S.
Ni, Chun-Lun
Lin, Chih-Chun
Pan, Ming-Kai
Louis, Elan D.
Marks, Andrew R.
Kuo, Sheng-Han
Faust, Phyllis L. http://orcid.org/0000-0001-6533-7921
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01 NS124854, R01 NS088257, R01 NS117745, R01 NS104423, R01 NS118179, R01 086736, 1RF1 NS114570)
National Heart, Lung, and Blood Institute (T32 HL120826, R01 HL145473, R01 HL142903, R01HL140934, R25 HL156002)
National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK118240)
Article History
Received: 27 March 2023
Revised: 6 June 2023
Accepted: 14 June 2023
First Online: 19 June 2023
Declarations
:
: ARM and Columbia University own shares in ARMGO Pharma, Inc. a biotech company developing RyR targeted therapeutics. All other authors declare no competing interests or conflicts.